Abstract：
The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerated phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagnosed Ph-positive chronic phase CML. This review details the efficacy of bosutinib for the treatment of CML in the first- and second-line settings, as well as in third- and later-line settings for high-risk patients resistant or intolerant to at least 2 TKIs. It also outlines bosutinib studies that provide evidence for dose-optimization strategies that can be used to improve efficacy and effectively manage adverse events. The studies that provide evidence for specific patient populations benefiting particularly from bosutinib dose-optimization strategies are also discussed. The well-established, long-term side-effect profile and the potential to make dose adjustments with bosutinib make it an appropriate treatment option for patients with CML. Bosutinib has demonstrated a positive impact on health-related quality of life and an important role in the long-term treatment of patients with CML.
摘要：
BCR::ABL1酪氨酸激酶抑制剂（TKIs）的发展已将费城染色体（Ph）阳性的慢性粒细胞白血病（CML）从一种致命的疾病转变为一种常见的惰性疾病，如果管理有效，可以恢复接近正常人群的预期寿命。Bosutinib是第二代TKI，被批准用于慢性阶段Ph阳性CML的成人，加速阶段,或对先前治疗有抗性或不耐受的爆炸期，以及新诊断的Ph阳性慢性期CML。这篇综述详细介绍了博舒替尼在一线和二线治疗CML的疗效。以及对至少2种TKIs耐药或不耐受的高风险患者的三线和后期设置。它还概述了博舒替尼研究，这些研究为剂量优化策略提供了证据，可用于提高疗效和有效管理不良事件。还讨论了为特定患者人群提供证据的研究，这些研究尤其是从博舒替尼剂量优化策略中受益。成熟的，博舒替尼的长期副作用和剂量调整的可能性使其成为CML患者的合适治疗选择.博舒替尼已证明对健康相关生活质量有积极影响，并在CML患者的长期治疗中发挥重要作用。
